SecBot SecBot
8-K ·Filed Aug 12, 2026

MDGL

MADRIGAL PHARMACEUTICALS, INC.
NEUTRAL
Impact 3/10
Horizonimmediate Processed3mo ago SEC0001628280-26-055962
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

This is a routine board appointment with no immediate trading implications. Monitor for any future strategic shifts in R&D direction that Dr. Reed's presence might influence, but no catalyst is present here.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$536.20
T+0 close · Aug 12, 2026 · via day close
Latest settled
−25.38%
T+60 · $400.10
Vs SPY
−20.27%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 12 $536.20entry
  2. T+1 · 3mo ago −5.38%α −6.07% · $507.37
  3. T+5 · 3mo ago +0.74%α +1.18% · $540.16
  4. T+20 · 2mo ago −0.57%α +1.32% · $533.12
  5. T+60 · 12d ago −25.38%α −20.27% · $400.10
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Madrigal Pharmaceuticals appointed John C. Reed, M.D., Ph.D., a top R&D executive from Johnson & Johnson, to its Board of Directors, expanding the board from eight to nine members. This is a routine governance move that adds significant scientific and industry expertise but provides no new financial data or strategic catalysts for the stock.

Key Facts

  • Board expanded from 8 to 9 members with the appointment of John C. Reed, M.D., Ph.D.
  • Dr. Reed is Executive Vice President, Innovative Medicine, R&D at Johnson & Johnson and a member of its Executive Committee.
  • Dr. Reed will receive an annual cash retainer of $50,000, a $10,000 committee fee, and an initial equity grant valued at $675,000 (50% options, 50% RSUs).
  • Dr. Reed was appointed to the Science and Technology Committee.
  • No material financial data, guidance, or operational updates were provided in this filing.

Financial Impact

No financial impact from this board appointment. Director compensation is standard and immaterial relative to a $12.4B market cap.

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (24 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-055962
Document: pressrelease-boardappointm.htm0001628280-26-055962
Document: 0001628280-26-055962-index-headers.html0001628280-26-055962
Document: 0001628280-26-055962-index.html0001628280-26-055962
Document: 0001628280-26-055962.txt0001628280-26-055962

Track record

18 reports on MDGL

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +10.26% at T+20 after the Jul 30, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
  2. Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  3. Nov 6, 202610d ago Insider Buy Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  4. Nov 6, 202610d ago Insider Cluster Bullish 5/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  5. Nov 6, 202610d ago 144 Neutral 2/10 Entry $432.79 to $423.96 Now $423.96 −2.04% ▼ −2.04% −0.35% vs SPY
  6. Nov 5, 202611d ago Institutional Cluster Mixed 3/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
  7. Nov 5, 202611d ago Press Release Bullish 5/10 Entry $400.10 to $425.21 Now $423.96 +5.96% ▲ +6.28% +2.99% vs SPY
  8. Nov 3, 202613d ago 8-K Bullish 7/10 No price data
  9. Nov 3, 202613d ago Press Release Bullish 6/10 Entry $396.32 to $432.60 Now $423.96 +6.97% ▲ +9.15% +9.74% vs SPY
  10. Aug 12, 202613w ago 8-K Neutral 3/10 Viewing Entry $536.20 to $540.16 Now $423.96 −20.93% ▲ +0.74% +1.18% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens Wed (10h 55m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 12, 2026